Evidence map›Paper›PMID 41695286›Full record

ArticleWorld journal of gastroenterology2026

Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation.

Mei-Yuan Zhang, Rui-Qian Sun, Qi Min, Yu-Qi Zhu, Shu-Kui Qin, Qing-Long Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mei-Yuan ZhangIntensive Care Unit, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine/Shanghai Key Laboratory of Embryo Original Disease, Shanghai Municipal Key Clinical Specialty, Shanghai 201499, China. zhangmeiyuan1972@163.com.
Rui-Qian SunDepartment of Integrated Traditional Chinese and Western Medicine Clinical Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
Qi MinDepartment of Integrated Traditional Chinese and Western Medicine Clinical Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
Yu-Qi ZhuDepartment of Integrated Traditional Chinese and Western Medicine Clinical Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
Shu-Kui QinDepartment of Integrated Traditional Chinese and Western Medicine Clinical Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
Qing-Long GuoDepartment of Clinical Pharmacy, Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210018, Jiangsu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical application of donafenib in advanced hepatocellular carcinoma (HCC) is restricted by its limited therapeutic efficacy and a variety of treatment-associated adverse events. These factors collectively underscore the need for more effective and well-tolerated therapeutic strategies.

aimTo investigate the effects and underlying mechanisms of oroxylin A in combination with donafenib on HCC through

methodsThe antitumor efficacy of oroxylin A, donafenib, and their combination was assessed in xenograft mouse models and MHCC-97H/PLC-PRF-5 cell lines. Tumor growth was monitored using fluorescence live imaging. Cell viability, colony formation, and apoptosis were assessed using Cell Counting Kit-8, clonogenic, and flow cytometry assays, respectively. Molecular mechanisms were investigated by assessing the expression of tumor protein p53 (TP53) signaling-related regulators

resultsThe combination of oroxylin A and donafenib demonstrated superior anti-tumor efficacy

conclusionOroxylin A and donafenib exert a synergistic anti-tumor effect in HCC by co-activating the TP53 signaling pathway through distinct but complementary molecular axes. This combination strategy presents a promising and viable therapeutic approach to overcome the limitations of donafenib monotherapy in the treatment of HCC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularFlavonoidsLiver NeoplasmsTumor Suppressor Protein p53AnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalDrug SynergismFemaleHumansMaleMiceMice, Inbred BALB C5,7-dihydroxy-6-methoxy-2-phenylchromen-4-oneFlavonoidsMAS1 protein, humanMDM2 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-mdm2TP53 protein, humanTumor Suppressor Protein p53Combination therapyDonafenibHepatocellular carcinomaOroxylin ATP53 signaling pathwayXenograft tumor

Identifiers

PMID41695286
PMCPMC12898113

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.